WALTHAM, Mass. & PARIS--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan family of products, today announces the publication of the “FibroScan-AST (FAST) Score For The ...

PARIS & WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan ® family of products, is pleased to announce its strong presence at the upcoming American ...

BALTIMORE (KFSN) -- Thirty million Americans, or one in 10, have some form of liver disease. It could be scarring from a hepatitis C infection, cirrhosis or even liver cancer. Doctors are now using a ...

According to the Centers for Disease Control and Prevention (CDC), approximately 25,000 men and 11,000 women are diagnosed with liver cancer each year. Early detection and treatment are key to ...

This article is brought to you by Our Lady of the Angels. An innovative non-invasive technology at Our Lady of the Angels is helping doctors better detect liver problems, leading to earlier treatment ...

WALTHAM, Mass., Feb. 26, 2024 /PRNewswire/ -- More than 100 million people in the U.S. are affected by some form of liver disease, but only 4.5 million adults have been diagnosed with the condition.

The Tri-State’s TRUSTED news source. Click here to stay informed and subscribe to Herald-Dispatch. Click #isupportlocal for more information on supporting our local journalists. SCOTT DEPOT, W.Va. — ...

Background: FibroTest (FT) is the most frequently used serum fibrosis marker and consists of an algorithm of five fibrosis markers (alfa2-macroglobulin, apolipoproteinA1, haptoglobin, GGT, bilirubin).

At present, transient elastography and the serum marker FibroTest are the most intensively evaluated non-invasive methods for the assessment of liver fibrosis. The results of the present study for ...